相关实验视频
Updated: Jun 4, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.4K
基因型导向喘治疗减少了儿童的恶化:对两项随机对照试验的元分析
Elise M A Slob1,2,3, Susanne J H Vijverberg1, Tom Ruffles4,5
1Department of Pulmonary Medicine, AmsterdamUMC, University of Amsterdam, Amsterdam, The Netherlands.
Allergy
|December 26, 2024
概括
对患有喘的儿童进行基因型导向治疗可能会减少喘恶化. 这种方法通过考虑ADRB2Arg16Gly多态 (rs1042713) 进行逐步治疗决策来个性化护理.
科学领域:
- 药物基因组学 药物基因组学
- 儿科肺病学 儿科肺病学
- 喘管理 喘管理
背景情况:
- 吸入性皮质类固醇 (ICS) 和长效β2-激动剂 (LABA) 是标准的喘治疗方法.
- 一些儿童对LABA补充疗法反应不佳,可能是由于ADRB2 Arg16Gly多态 (rs1042713) 的原因.
- 尽管使用LABA,但A等位基因 (Arg16) 与恶化的增加有关.
研究的目的:
- 调查基因型导向治疗是否能改善儿童喘的结果.
- 评估ADRB2Arg16Gly多态化对治疗反应的影响.
- 根据基因分析评估喘控制和恶化率.
主要方法:
- 两个随机对照试验 (PUFFIN和PACT) 的个人参与者数据元分析.
- 在ICS上包括患有未控制喘的儿童 (6-18岁),需要加强治疗.
- 随机选择以基因型为指导的治疗 (Gly16/Gly16的LABA;Arg16/Arg16或Arg16/Gly16的双 ICS或蒙特卢卡斯特) 或对照.
主要成果:
- 在193名儿童中,喘控制在各组之间没有显著差异.
- 基因型导向治疗导致喘恶化率显著降低 (p=0.04).
- 在59%的参与者中,A等位基因 (Arg16) 存在.
结论:
- 基因型导向的升级性喘治疗可能会降低儿童的恶化率.
- 这种个性化的方法可以增强喘护理策略.
- 进一步的研究可能会验证优化儿科喘管理的基因分析.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:20Asthma: Pathogenesis and Management
348
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
348
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
232
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
232